Molecular Imaging and Precision Medicine in Lung Cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  PET Clinics

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1016/j.cpet.2016.08.008PMID 27863566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer – does it change therapeutic decisions in comparison to 18F-FDG PET/CT?

  2017cited by this paper
• The Current and Evolving Role of PET in Personalized Management of Lung Cancer.

  2016cited by this paper
• PET/CT of Lung Cancer

  2016cited by this paper
• Identification of false‐negative and false‐positive diagnoses of lymph node metastases in non‐small cell lung cancer patients staged by integrated 18F‐fluorodeoxyglucose‐positron emission tomography/computed tomography: A retrospective cohort study

  2016cited by this paper
• Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer.

  2016cited by this paper
• Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.

  2016cited by this paper
• Recent Trends in the Identification of Incidental Pulmonary Nodules.

  2015cited by this paper
• Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.

  2015cited by this paper
• Prognostic Value of Total Lesion Glycolysis by 18F-FDG PET/CT in Surgically Resected Stage IA Non–Small Cell Lung Cancer

  2015cited by this paper
• Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.

  2015cited by this paper
• 18F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer

  2014cited by this paper
• NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism.

  2014cited by this paper
• Timing of Metabolic Response Monitoring During Erlotinib Treatment in Non–Small Cell Lung Cancer

  2014cited by this paper
• [18F]FDG Positron Emission Tomography within Two Weeks of Starting Erlotinib Therapy Can Predict Response in Non-Small Cell Lung Cancer Patients

  2014cited by this paper
• Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

  2014cited by this paper
• Magnetic Resonance Imaging Visualization of Vulnerable Atherosclerotic Plaques at the Brachiocephalic Artery of Apolipoprotein E Knockout Mice by the Blood-Pool Contrast Agent B22956/1

  2014cited by this paper
• Heterogeneity in [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Non–Small Cell Lung Carcinoma and Its Relationship to Metabolic Parameters and Pathologic Staging

  2014cited by this paper
• Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.

  2014cited by this paper
• Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

  2013cited by this paper
• Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

  2013influential reference
• Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.

  2012cited by this paper
• Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?

  2012cited by this paper
• Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system.

  2012cited by this paper
• Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung

  2011cited by this paper
• Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.

  2011cited by this paper
• 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

  2011cited by this paper
• Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET

  2011cited by this paper
• Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging.

  2011influential reference
• Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial

  2010cited by this paper
• From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

  2009cited by this paper
• Prognostic value of FDG uptake in early stage non-small cell lung cancer.

  2008cited by this paper
• Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).

  2008cited by this paper
• Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer

  2008cited by this paper
• Recommendations on the Use of 18F-FDG PET in Oncology

  2008cited by this paper
• Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.

  2008cited by this paper
• Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)

  2008cited by this paper
• Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy.

  2008cited by this paper
• [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung

  2008cited by this paper
• Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.

  2008cited by this paper
• Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.

  2008cited by this paper
• 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer

  2007cited by this paper
• Metabolic tumor burden predicts for disease progression and death in lung cancer.

  2007cited by this paper
• Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging.

  2007cited by this paper
• Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.

  2006cited by this paper
• Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma

  2006cited by this paper
• FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.

  2005cited by this paper
• The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.

  2005cited by this paper
• Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure.

  2005cited by this paper
• Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.

  2005cited by this paper
• Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.

  2005cited by this paper
• Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation.

  2004cited by this paper
• Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.

  2003cited by this paper
• Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.

  2003cited by this paper
• Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.

  2003cited by this paper
• Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

  2003cited by this paper
• Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.

  2003cited by this paper
• Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.

  2003cited by this paper
• Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with NonSmall-Cell Lung Cancer

  2003cited by this paper
• Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

  2003cited by this paper
• Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

  2003cited by this paper
• A tabulated summary of the FDG PET literature.

  2002cited by this paper
• A tabulated summary of the FDG PET literature.

  2001cited by this paper
• High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.

  2001cited by this paper
• [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].

  2001cited by this paper
• Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.

  2001cited by this paper
• Accuracy of Positron Emission Tomography for Diagnosis of Pulmonary Nodules and Mass Lesions: A Meta-analysis

  2001cited by this paper
• Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

  1999cited by this paper
• Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases.

  1998cited by this paper
• Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.

  1998cited by this paper
• The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

  1998cited by this paper
• Frequency of extrathoracic metastases from bronchogenic carcinoma in patients with normal-sized hilar and mediastinal lymph nodes on CT.

  1988cited by this paper
• On respiratory impairment in cancer cells.

  1956cited by this paper
• On respiratory impairment in cancer cells.

  1956cited by this paper
• THE METABOLISM OF TUMOURS

  1931cited by this paper
• THE METABOLISM OF TUMORS IN THE BODY

  1927cited by this paper

• Delta Changes in [18F]FDG PET/CT Parameters Can Prognosticate Clinical Outcomes in Recurrent NSCLC Patients Who Have Undergone Reirradiation–Chemoimmunotherapy

  2025cites this paper
• Characteristics of fibrotic-foci-like lung adenocarcinoma on 18F-FDG PET/computed tomography and HRCT

  2023cites this paper
• Detection and Independent Validation of Model-Based Quantitative Transcriptional Regulation Relationships Altered in Lung Cancers

  2020cites this paper
• SP70-Targeted Imaging for the Early Detection of Lung Adenocarcinoma

  2020cites this paper
• DriverDBv3: a multi-omics database for cancer driver gene research

  2019cites this paper
• Lung on FDG PET/CT

  2019cites this paper
• Evaluation of Flavonoid Derivative and Doxorubicin Effects in Lung Cancer Cells (A549) Using Differential Pulse Voltammetry Method

  2018cites this paper
• A novel stereotactic frame for real PET-guided biopsies: A preclinical proof-of-concept.

  2017cites this paper
• Generation of a co-culture cell micropattern model to simulate lung cancer bone metastasis for anti-cancer drug evaluation

  2017cites this paper
• 定量影像学在肺癌放/化疗疗效评估中的应用

  2017cites this paper